Skip to main navigation Skip to search Skip to main content

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

  • C. Martínez
  • , C. Canals
  • , B. Sarina
  • , E. P. Alessandrino
  • , D. Karakasis
  • , A. Pulsoni
  • , Simona Sica
  • , M. Trneny
  • , J. A. Snowden
  • , E. Kanfer
  • , N. Milpied
  • , A. Bosi
  • , S. Guidi
  • , C. A. De Souza
  • , R. Willemze
  • , R. Arranz
  • , L. Jebavy
  • , A. Hellmann
  • , D. Sibon
  • , R. Oneto
  • J. J. Luan, P. Dreger, L. Castagna, A. Sureda
  • Hematology, Hospital Clínic
  • Hematology, Hospital Santa Creu i Sant Pau
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • IRCCS Fondazione Policlinico San Matteo - Pavia
  • Evagelismos Hospital
  • University of Rome La Sapienza
  • Institute of Hematology and Blood Transfusion
  • Sheffield Teaching Hospitals NHS Foundation Trust
  • Hammersmith Hospital
  • Hopital Haut-Lévêque C.H.U de Bordeaux
  • Azienda Ospedaliera Careggi
  • Universidade Estadual de Campinas
  • Leiden University
  • Hospital Universitario de la Princesa
  • Charles University
  • Medical University of Gdańsk
  • Université Paris Cité
  • BMT Registry - GITMO
  • Sorbonne Université
  • Heidelberg University 

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT.
Original languageEnglish
Pages (from-to)2430-2434
Number of pages5
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume24
DOIs
Publication statusPublished - 2013

Keywords

  • Hodgkin's lymphoma
  • autologous stem cell transplantation
  • relapse

Fingerprint

Dive into the research topics of 'Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation'. Together they form a unique fingerprint.

Cite this